Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Q3 2016 Earnings Presentation
28 slides from Cytosorbents's earnings presentation, Nov 7, 2016
Slide 1: CytoSorbents Corporation Q3 2016 Earnings Conference Call
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q3 2016 Earnings Conference Call November 7, 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents is A Leader in Critical Care Immunotherapy
CytoSorbents is A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: CytoSorb Removes the Fuel to the Fire
CytoSorb® Removes the Fuel to the Fire • CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Approved for use in any situation where cytokines are elevated • Removes cy
Slide 5: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 5
Slide 6: The World Needs CytoSorb
Suspect The World Needs CytoSorh® | | | Save Lives — Xx sia CvtoSorvents Working to Save Lives Through Blood Purification
Slide 7: Financial Highlights
Financial Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 8: Q3 2016 Comparative Revenue Results
Q3 2016 Comparative Revenue Results 3 Months 3 Months Ended Sept Ended Sept 30, 2016 30, 2015 % Incr. Product revenue $ 2,143,116 $ 1,071,459 100% Grant and other income 268,592 272,166 (1)% Total revenue $ 2,411,708 $ 1,343,625 79% • CytoSorb® product sales doubled to $2.14M for Q3 2016, compared t
Slide 9: Quarterly Product Sales
Quarterly Product Sales Sixth consecutive quarter of product sales growth Fifth consecutive quarter of record sales $2,143,116 CytoSorb® Product Sales $2,000,000 $1,852,670 $1,597,449 $1,495,590 $1,500,000 $1,071,459 $1,031,761 $1,000,000 $871,150 $773,112 $703,658 $663,233 $569,243 $500,000 $314,15
Slide 10: Comparative 9-Month Revenue Results
Comparative 9-Month Revenue Results 9 Months 9 Months Ended Sept Ended Sept 30, 2016 30, 2015 % Incr. Product revenue $ 5,593,235 $ 2,548,229 119% Grant and other income 850,993 482,393 76% Total revenue $ 6,444,228 $ 3,030,622 113% • CytoSorb® product sales for the first nine months of fiscal 2016
Slide 11: Trailing Twelve Months Product Sales
Trailing Twelve Months Product Sales Over the past three years, the compound growth rate of return (“CAGR”) on product sales was 128% $8,000,000 Trailing Twelve Month Product Sales $7,088,825 $7,000,000 $6,000,000 $5,000,000 Trend Line $4,000,000 $3,419,379 $3,000,000 $2,578,396 $2,000,000 $1,000,00
Slide 12: CytoSorb Distributed in 42 Countries
CytoSorb® Distributed in 42 Countries IntensivMed WMC 12
Slide 13: Working Capital and Cap Table
Working Capital and Cap Table Working Capital as of 9/30/16 12/31/15 12/31/14 12/31/13 12/31/12 Current Assets: Cash and short-term investments $ 6,375 $ 7,509 $ 5,550 $ 2,183 $ 1,729 Grants and accounts receivable, net 1,406 649 819 453 51 Inventories 1,052 1,191 538 245 682 Prepaid expenses and ot
Slide 14: Driving Toward Operating Profitability
Driving Toward Operating Profitability Product sales continue to grow rapidly while increases in fixed non-clinical, non-cash expenses taper off Product Revenue vs. Fixed Operating Expense Trends 10,000,000 9,000,000 8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 - 2
Slide 15: Operating Highlights
Operating Highlights med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 16: U.S. REFRESH I Trial – Safety Confirmed
U.S. REFRESH I Trial – Safety Confirmed REduction in FREe Hemoglobin • 40-patient, eight-center study evaluating the safety and efficacy of intra- operative use of CytoSorb® in a heart-lung machine during complex cardiac surgery in elective, non-emergent cardiac surgery > 3 hours • Aortic reconstruc
Slide 17: REFRESH I Trial – Safety
REFRESH I Trial – Safety REduction in FREe Hemoglobin Trial • A total of 46 patients were enrolled with ~40 patients with evaluable biomarker data • The Data Safety Monitoring Board (DSMB) evaluated all adverse and serious adverse events in the control and treatment arms, and concluded there was no
Slide 18: More Studies Underway
More Studies Underway • Broad clinical program in Europe with 58 investigator-initiated studies in various stages, including several that have completed and nearly half have started and/or are enrolling • These studies run the gamut from sepsis, cardiac surgery, post-operative inflammation, liver fa
Slide 19: Three Major Partnerships, Potential for More
Three Major Partnerships, Potential for More Critical Care or Cardiac Catheters Renal Surgery Dialysis Biotech and Blood Transfusion Immunotherapy *Companies listed here are used simply as examples of companies in these respective 19 verticals. We make no other representations to our relationship wi
Slide 20: Partnership
Partnership • Entered into a multi-year partnership with Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery, for cardiac surgery applications • Initial exclusive distribution of CytoSorb® in France, Denmark, Norway, Sweden, Finland, and Iceland • Terumo
Slide 21: Strong Technology Validation of CytoSorb
Strong Technology Validation of CytoSorb $18M in Grant 17,000 and Contract Human Treatments Funding and Growing 21
Slide 22: Advanced Development of CytoSorb-XL
Advanced Development of CytoSorb-XL • CytoSorb-XL is a next generation porous polymer bead technology combining lipopolysaccharide (LPS) endotoxin removal with the robust cytokine, toxin, and inflammatory mediator reduction achieved by CytoSorb® • Endotoxin is a very potent stimulator of cytokine st
Slide 23: Newly Launched Corporate Website
Newly Launched Corporate Website Please visit us at www.cytosorbents.com 23
Slide 24: Increasing Media Coverage
Increasing Media Coverage 24
Slide 25: Increasing Analyst Coverage
Increasing Analyst Coverage 25
Slide 26: Outlook for 2H 2016
Outlook for 2H 2016 • CytoSorbents has not historically given financial guidance on quarterly results until the quarter has been completed. • However, we currently expect a strong Q4 2016, with the achievement of numerous operating milestones • In addition, we reiterate our guidance that we expect s
Slide 27: CytoSorb SIRS and Sepsis: Regain Control!
CytoSorb® SIRS and Sepsis: Regain Control! 27
Slide 28: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ: CTSO Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 pchan@cytosorbents.com A Leader in Critical Care Immunotherapy 28